WallStSmart

Merck & Company Inc (MRK)vsZhongchao Inc (ZCMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 585122% more annual revenue ($66.57B vs $11.38M). MRK leads profitability with a 4.8% profit margin vs -55.5%. MRK earns a higher WallStSmart Score of 36/100 (F).

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

ZCMD

Avoid

29

out of 100

Grade: F

Growth: 2.0Profit: 2.0Value: 6.7Quality: 8.0
Piotroski: 1/9Altman Z: 7.52
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-73.7%)

Margin of Safety

-73.7%

Fair Value

$82.84

Current Price

$143.93

$61.09 premium

UndervaluedFair: $82.84Overvalued
ZCMDUndervalued (+89.3%)

Margin of Safety

+89.3%

Fair Value

$2.28

Current Price

$0.80

$1.48 discount

UndervaluedFair: $2.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$355.10B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

ZCMD3 strengths · Avg: 10.0/10
Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.5210/10

Safe zone — low bankruptcy risk

Areas to Watch

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

ZCMD4 concerns · Avg: 2.5/10
Market CapQuality
$5.24M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-37.3%2/10

ROE of -37.3% — below average capital efficiency

Revenue GrowthGrowth
-23.2%2/10

Revenue declined 23.2%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bull Case : ZCMD

The strongest argument for ZCMD centers on Price/Book, Debt/Equity, Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Bear Case : ZCMD

The primary concerns for ZCMD are Market Cap, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

MRK profiles as a value stock while ZCMD is a turnaround play — different risk/reward profiles.

MRK carries more volatility with a beta of 0.23 — expect wider price swings.

MRK is growing revenue faster at 5.1% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 29/100). ZCMD offers better value entry with a 89.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Zhongchao Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · China

Zhongchao Inc. provides health care information, education and training services in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.

Visit Website →

Want to dig deeper into these stocks?